Oramed Pharmaceuticals Given New $30.00 Price Target at Aegis (ORMP)
Equities researchers at Aegis raised their price target on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from $25.00 to $30.00 in a research report issued on Wednesday, Analyst RN reports. The firm currently has a “buy” rating on the stock. Aegis’ target price suggests a potential upside of 59.91% from the company’s current price.
Oramed Pharmaceuticals (NASDAQ:ORMP) traded up 15.78% on Wednesday, hitting $21.72. 393,431 shares of the company’s stock traded hands. Oramed Pharmaceuticals has a 52-week low of $4.56 and a 52-week high of $19.29. The stock’s 50-day moving average is $10.16 and its 200-day moving average is $7.72. The company’s market cap is $172.6 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at MLV Capital initiated coverage on shares of Oramed Pharmaceuticals in a research note to investors on Tuesday. They set a “buy” rating and a $27.00 price target on the stock. Analysts at Capital Ideas Research initiated coverage on shares of Oramed Pharmaceuticals in a research note to investors on Tuesday, December 3rd. They set a “buy” rating on the stock.
Oramed Pharmaceuticals Inc is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.